$CYDY CytoDyn Annual shareholders meeting discus
Post# of 89062
Annual shareholders meeting discussed Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
https://www.cytodyn.com/newsroom/press-releas...meeting-of